AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Shots:
- The approval is based on P-IIIb EXPEDITION-8 study assessing Maviret in 343 treatment naïve chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks.
- The P-IIIb EXPEDITION-8 study results: GT1- 6 patients achieving SVR12 (97.7%); GT3 patients achieving SVR12 (95.2%); one case of virologic failure and no case of discontinuation was reported
- Maviret is a combination of NS3/4A protease & NS5A inhibitor and is now available as an 8-week regimen for treatment-naïve- HCV patients without cirrhosis & with compensated cirrhosis- regardless of genotype in the EU
Click here to read full press release/ article
Ref: AbbVie | Image: AbbVie
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com